or Try an Advanced Search...

    Portola Pharmaceuticals Stocks List

    Symbol Grade Name % Change
    BIIB C Biogen Idec Inc. 0.61
    RIGL F Rigel Pharmaceuticals, Inc. 3.81
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Lupus Adenosine Alzheimer's Disease Asthma Autoimmune Disease Autoimmune Disorders Biotechnology Cancer Cancer Cell Cd20 Chemical Compounds Chronic Lymphocytic Leukemia Clinical Trial Product Clinical Trial Products Daiichi Sankyo Degenerative Disease Disability Discoid Lupus Drug Development Enzymes

    Related ETFs - A few ETFs which own one or more of the above listed Portola Pharmaceuticals stocks.

    Symbol Grade Name Weight
    BIS B ProShares UltraShort Nasdaq Biotechnology 6.12
    PBE C PowerShares Dynamic Biotech & Genome 4.61
    DIP A BTD Capital Fund 4.41
    BBH D Market Vectors Biotech ETF 4.17
    IBRN C iShares Neuroscience and Healthcare ETF 4.16
    View all Portola Pharmaceuticals ETFs...
    Compare ETFs
    Compare BIS to BBH Compare DIP to IBRN Compare PBE to BBH

        Portola Pharmaceuticals Stocks Recent News

        Date Stock Title
        May 1 BIIB Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
        Apr 30 BIIB Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings
        Apr 30 BIIB Biogen: Don't Overthink This One
        Apr 29 BIIB The Analyst Landscape: 27 Takes On Biogen
        Apr 29 BIIB 10 Most Promising Stocks to Buy Before They Take Off
        Apr 29 BIIB Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)
        Apr 29 BIIB Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
        Apr 28 BIIB Biogen First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
        Apr 27 BIIB Biogen Inc. (NASDAQ:BIIB) Just Released Its First-Quarter Earnings: Here's What Analysts Think
        Apr 26 BIIB Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
        Apr 26 BIIB The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
        Apr 26 BIIB Decoding Biogen Inc (BIIB): A Strategic SWOT Insight
        Apr 25 BIIB Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
        Apr 25 BIIB Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
        Apr 25 BIIB Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript
        Apr 25 BIIB Shareholders 30% loss in Biogen (NASDAQ:BIIB) partly attributable to the company's decline in earnings over past year
        Apr 25 BIIB For Beaten-Down Maker of Alzheimer’s Drug, Good Enough Will Do
        Apr 25 BIIB Q1 2024 Biogen Inc Earnings Call
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Lupus Adenosine Alzheimer's Disease Asthma Autoimmune Disease Autoimmune Disorders Biotechnology Cancer Cancer Cell Cd20 Chemical Compounds Chronic Lymphocytic Leukemia Clinical Trial Product Clinical Trial Products Daiichi Sankyo Degenerative Disease Disability Discoid Lupus Drug Development Enzymes
        Portola Pharmaceuticals

        Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops and commercializes drugs. The company focuses primarily on drugs used in the treatment of thrombosis and hematological malignancies.
        Headquartered and founded in South San Francisco, California, Portola Pharmaceuticals is a member of the NASDAQ Biotechnology Index.

        More about Portola Pharmaceuticals
        Browse All Tags